215 related articles for article (PubMed ID: 10535758)
1. Antiplatelet effect of amlodipine: a possible mechanism through a nitric oxide-mediated process.
Chou TC; Li CY; Yen MH; Ding YA
Biochem Pharmacol; 1999 Nov; 58(10):1657-63. PubMed ID: 10535758
[TBL] [Abstract][Full Text] [Related]
2. The role of inhibition of nitric oxide synthesis in the aggregation of platelets due to the stimulated production of thromboxane A2.
Banerjee D; Mazumder S; Sinha AK
Blood Coagul Fibrinolysis; 2014 Sep; 25(6):585-91. PubMed ID: 25083729
[TBL] [Abstract][Full Text] [Related]
3. Enhanced nitric oxide and cyclic GMP formation plays a role in the anti-platelet activity of simvastatin.
Chou TC; Lin YF; Wu WC; Chu KM
Br J Pharmacol; 2008 Mar; 153(6):1281-7. PubMed ID: 18264124
[TBL] [Abstract][Full Text] [Related]
4. Mechanism of inhibition of platelet aggregation by rutaecarpine, an alkaloid isolated from Evodia rutaecarpa.
Sheu JR; Hung WC; Lee YM; Yen MH
Eur J Pharmacol; 1996 Dec; 318(2-3):469-75. PubMed ID: 9016940
[TBL] [Abstract][Full Text] [Related]
5. Antiplatelet effect of the anaesthetic drug propofol: influence of red blood cells and leucocytes.
De La Cruz JP; Páez MV; Carmona JA; De La Cuesta FS
Br J Pharmacol; 1999 Dec; 128(7):1538-44. PubMed ID: 10602334
[TBL] [Abstract][Full Text] [Related]
6. Differential inhibition of human platelet aggregation and thromboxane A2 formation by L-arginine in vivo and in vitro.
Bode-Böger SM; Böger RH; Galland A; Frölich JC
Naunyn Schmiedebergs Arch Pharmacol; 1998 Feb; 357(2):143-50. PubMed ID: 9521487
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet effect of marchantinquinone, isolated from Reboulia hemisphaerica, in rabbit washed platelets.
Liao CH; Ko FN; Wu CL; Teng CM
J Pharm Pharmacol; 2000 Mar; 52(3):353-9. PubMed ID: 10757426
[TBL] [Abstract][Full Text] [Related]
8. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase.
Wu CC; Ko FN; Kuo SC; Lee FY; Teng CM
Br J Pharmacol; 1995 Oct; 116(3):1973-8. PubMed ID: 8640334
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the L-arginine:nitric oxide pathway in human platelets.
Radomski MW; Palmer RM; Moncada S
Br J Pharmacol; 1990 Oct; 101(2):325-8. PubMed ID: 1701676
[TBL] [Abstract][Full Text] [Related]
10. Cyclic AMP and cyclic GMP phosphodiesterase inhibition by an antiplatelet agent, 6-[(3-methylene-2-oxo-5-phenyl-5-tetrahydrofuranyl)methoxy)quinol inone (CCT-62).
Liao CH; Tzeng CC; Teng CM
Eur J Pharmacol; 1998 May; 349(1):107-14. PubMed ID: 9669503
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms involved in the antiplatelet activity of Escherichia coli lipopolysaccharide in human platelets.
Sheu JR; Hung WC; Kan YC; Lee YM; Yen MH
Br J Haematol; 1998 Oct; 103(1):29-38. PubMed ID: 9792285
[TBL] [Abstract][Full Text] [Related]
12. The calcium modulator nifedipine exerts its antiaggregatory property via a nitric oxide mediated process.
Berkels R; Klaus W; Boller M; Rösen R
Thromb Haemost; 1994 Aug; 72(2):309-12. PubMed ID: 7831670
[TBL] [Abstract][Full Text] [Related]
13. Effect of trilinolein on cyclic nucleotide formation in human platelets: relationship with its antiplatelet effect and nitric oxide synthesis.
Shen YC; Hong CY
Br J Pharmacol; 1995 Sep; 116(1):1644-8. PubMed ID: 8564231
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms involved in the antiplatelet activity of 8-methyl-4-(1-piperazinyl)-7-(3-pyridinylmethoxy)-2H-1-benzopyran-2-one (RC414).
Leoncini G; Signorello MG; Bruzzese D; Di Braccio M; Grossi GC; Roma G
Biochem Pharmacol; 2004 Mar; 67(5):911-8. PubMed ID: 15104244
[TBL] [Abstract][Full Text] [Related]
15. Relaxin depresses platelet aggregation: in vitro studies on isolated human and rabbit platelets.
Bani D; Bigazzi M; Masini E; Bani G; Sacchi TB
Lab Invest; 1995 Nov; 73(5):709-16. PubMed ID: 7474945
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities.
Nagakura N; Saeki T; Harada K; Yoshitake S; Kobayashi S; Yamanaka T; Saito I
Biol Pharm Bull; 1996 Jun; 19(6):828-33. PubMed ID: 8799481
[TBL] [Abstract][Full Text] [Related]
17. Antiplatelet effect of demethyldiisoeugenol.
Liao CH; Ko FN; Kuo YH; Teng CM
Can J Physiol Pharmacol; 1996 Oct; 74(10):1111-6. PubMed ID: 9022830
[TBL] [Abstract][Full Text] [Related]
18. Antiplatelet activity of Staphylococcus aureus lipoteichoic acid is mediated through a cyclic AMP pathway.
Sheu JR; Hsiao G; Lee C; Chang W; Lee LW; Su CH; Lin CH
Thromb Res; 2000 Aug; 99(3):249-58. PubMed ID: 10942791
[TBL] [Abstract][Full Text] [Related]
19. The antiplatelet activity of Escherichia coli lipopolysaccharide is mediated through a nitric oxide/cyclic GMP pathway.
Sheu JR; Hung WC; Su CH; Lin CH; Lee LW; Lee YM; Yen MH
Eur J Haematol; 1999 May; 62(5):317-26. PubMed ID: 10359060
[TBL] [Abstract][Full Text] [Related]
20. Direct inhibition of platelet function by organic nitrates via nitric oxide formation.
Weber AA; Strobach H; Schrör K
Eur J Pharmacol; 1993 Sep; 247(1):29-37. PubMed ID: 8258358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
